|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,187.00 INR | -1.77% |
|
-2.70% | -0.43% |
| 27/02 | Mankind Pharma says tax penalty of 10.2 million rupees dropped | RE |
| 16/02 | Mankind Pharma says tax penalty of 4.6 million rupees dropped | RE |
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | 17.37 | 15.12 | 10.52 | 12.41 | 7.57 | ||
Return on Total Capital | 22.22 | 19.01 | 13.24 | 15.3 | 9.16 | ||
Return On Equity % | 30.3 | 25.99 | 18.79 | 22.58 | 16.62 | ||
Return on Common Equity | 30.84 | 26.36 | 18.86 | 22.77 | 16.77 | ||
Margin Analysis | |||||||
Gross Profit Margin % | 70.32 | 68.03 | 65.68 | 67.87 | 70.02 | ||
SG&A Margin | 29.03 | 26.9 | 26.43 | 28.08 | 28.45 | ||
EBITDA Margin % | 27.38 | 26.17 | 21.77 | 24.54 | 24.49 | ||
EBITA Margin % | 25.72 | 24.39 | 19.91 | 22.31 | 22.46 | ||
EBIT Margin % | 25.55 | 24.13 | 18.15 | 20.82 | 19.72 | ||
Income From Continuing Operations Margin % | 20.78 | 18.67 | 14.97 | 18.79 | 16.44 | ||
Net Income Margin % | 20.33 | 18.42 | 14.65 | 18.51 | 16.31 | ||
Net Avail. For Common Margin % | 20.33 | 18.42 | 14.65 | 18.51 | 16.27 | ||
Normalized Net Income Margin | 15.89 | 14.7 | 11.38 | 13.48 | 11.08 | ||
Levered Free Cash Flow Margin | 9.44 | -20.85 | 8.13 | 11.75 | 6.27 | ||
Unlevered Free Cash Flow Margin | 9.64 | -20.4 | 8.42 | 11.93 | 8.42 | ||
Asset Turnover | |||||||
Asset Turnover | 1.09 | 1 | 0.93 | 0.95 | 0.61 | ||
Fixed Assets Turnover | 3.23 | 3.55 | 3.24 | 3.36 | 3.84 | ||
Receivables Turnover (Average Receivables) | 14.45 | 21.65 | 18.14 | 14.51 | 10.23 | ||
Inventory Turnover (Average Inventory) | 1.77 | 1.69 | 1.84 | 2.18 | 2.01 | ||
Short Term Liquidity | |||||||
Current Ratio | 2.89 | 1.68 | 2.32 | 3.1 | 1.23 | ||
Quick Ratio | 1.78 | 0.64 | 1.14 | 2.02 | 0.73 | ||
Operating Cash Flow to Current Liabilities | 0.86 | 0.35 | 0.97 | 1.02 | 0.43 | ||
Days Sales Outstanding (Average Receivables) | 25.27 | 16.86 | 20.12 | 25.23 | 35.68 | ||
Days Outstanding Inventory (Average Inventory) | 205.77 | 215.94 | 198.03 | 168.19 | 181.88 | ||
Average Days Payable Outstanding | 120.9 | 103.82 | 138.78 | 114.45 | 83.02 | ||
Cash Conversion Cycle (Average Days) | 110.14 | 128.98 | 79.37 | 78.97 | 134.54 | ||
Long Term Solvency | |||||||
Total Debt/Equity | 5.75 | 13.99 | 2.23 | 2.16 | 58.42 | ||
Total Debt / Total Capital | 5.44 | 12.27 | 2.19 | 2.12 | 36.88 | ||
LT Debt/Equity | 1.27 | 0.83 | 0.37 | 0.34 | 38.03 | ||
Long-Term Debt / Total Capital | 1.2 | 0.72 | 0.36 | 0.33 | 24 | ||
Total Liabilities / Total Assets | 23.69 | 30.95 | 21.53 | 19.96 | 47.52 | ||
EBIT / Interest Expense | 82.67 | 33.66 | 39.44 | 75.24 | 5.72 | ||
EBITDA / Interest Expense | 88.67 | 36.56 | 47.4 | 88.86 | 7.13 | ||
(EBITDA - Capex) / Interest Expense | 72.64 | 28.22 | 27.81 | 77.83 | 6.04 | ||
Total Debt / EBITDA | 0.16 | 0.43 | 0.09 | 0.08 | 2.84 | ||
Net Debt / EBITDA | -1.01 | -0.19 | -0.71 | -1.25 | 1.99 | ||
Total Debt / (EBITDA - Capex) | 0.2 | 0.56 | 0.15 | 0.09 | 3.35 | ||
Net Debt / (EBITDA - Capex) | -1.24 | -0.24 | -1.21 | -1.43 | 2.36 | ||
Growth Over Prior Year | |||||||
Total Revenues, 1 Yr. Growth % | 6 | 25.22 | 12.44 | 18.12 | 18.98 | ||
Gross Profit, 1 Yr. Growth % | 10.8 | 21.21 | 8.55 | 22.06 | 22.9 | ||
EBITDA, 1 Yr. Growth % | 8.84 | 19.51 | -4.31 | 33.15 | 18.87 | ||
EBITA, 1 Yr. Growth % | 8.45 | 18.55 | -5.96 | 32.34 | 19.02 | ||
EBIT, 1 Yr. Growth % | 8.14 | 18.06 | -13.32 | 35.48 | 11.95 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 22.43 | 12.37 | -9.86 | 48.26 | 3.39 | ||
Net Income, 1 Yr. Growth % | 22.81 | 13.28 | -10.58 | 49.23 | 4.08 | ||
Normalized Net Income, 1 Yr. Growth % | 9.88 | 15.62 | -12.97 | 39.93 | -2.79 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | 22.82 | 13.27 | -10.57 | 49 | 2.98 | ||
Accounts Receivable, 1 Yr. Growth % | -37.75 | 17.41 | 48.5 | 47.16 | 81.35 | ||
Inventory, 1 Yr. Growth % | 31.63 | 48.73 | -14.87 | 3.67 | 34.78 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | 6.82 | 19.98 | 26.26 | 4.03 | 2.4 | ||
Total Assets, 1 Yr. Growth % | 25.61 | 43.55 | 6.21 | 23.14 | 132.04 | ||
Tangible Book Value, 1 Yr. Growth % | 36.17 | -9.02 | 32.77 | 35.77 | -129.74 | ||
Common Equity, 1 Yr. Growth % | 35.48 | 30.35 | 20.8 | 25.93 | 53.07 | ||
Cash From Operations, 1 Yr. Growth % | 9.1 | -19.12 | 97.15 | 18.7 | 12.12 | ||
Capital Expenditures, 1 Yr. Growth % | 35.29 | 52.21 | 69.73 | -60.03 | 46.13 | ||
Levered Free Cash Flow, 1 Yr. Growth % | -21.91 | -379.11 | -143.45 | 70.67 | -39.48 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | -21.71 | -367.56 | -145.97 | 67.26 | -19.77 | ||
Dividend Per Share, 1 Yr. Growth % | - | - | - | - | - | ||
Compound Annual Growth Rate Over Two Years | |||||||
Total Revenues, 2 Yr. CAGR % | 11.79 | 15.12 | 18.66 | 15.24 | 18.12 | ||
Gross Profit, 2 Yr. CAGR % | 16.44 | 15.77 | 14.71 | 15.11 | 21.96 | ||
EBITDA, 2 Yr. CAGR % | 34.95 | 14.05 | 5.74 | 12.87 | 25.27 | ||
EBITA, 2 Yr. CAGR % | 35.65 | 13.39 | 4.32 | 11.56 | 25.46 | ||
EBIT, 2 Yr. CAGR % | 35.24 | 12.99 | -0.06 | 8.37 | 23.11 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | 45.54 | 17.29 | 0.64 | 15.6 | 23.78 | ||
Net Income, 2 Yr. CAGR % | 47.9 | 17.95 | 0.65 | 15.52 | 24.63 | ||
Normalized Net Income, 2 Yr. CAGR % | 41.15 | 12.72 | 0.31 | 10.36 | 16.59 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | 47.91 | 17.95 | 0.65 | 15.44 | 23.85 | ||
Accounts Receivable, 2 Yr. CAGR % | 22.53 | -14.51 | 32.04 | 47.83 | 63.36 | ||
Inventory, 2 Yr. CAGR % | 20.07 | 39.92 | 12.52 | -6.06 | 18.2 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 8.92 | 13.21 | 23.08 | 14.61 | 3.21 | ||
Total Assets, 2 Yr. CAGR % | 24.48 | 34.28 | 23.47 | 14.36 | 69.03 | ||
Tangible Book Value, 2 Yr. CAGR % | 29.91 | 11.31 | 9.91 | 34.26 | -36.46 | ||
Common Equity, 2 Yr. CAGR % | 29.33 | 32.89 | 25.48 | 23.34 | 38.84 | ||
Cash From Operations, 2 Yr. CAGR % | 39.58 | -7.38 | 26.27 | 52.98 | 15.37 | ||
Capital Expenditures, 2 Yr. CAGR % | 1.79 | 42.8 | 60.73 | -17.64 | -23.58 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 46.83 | 10.65 | -13.88 | 3.67 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 43.96 | 11.44 | -12.31 | 18.11 | ||
Compound Annual Growth Rate Over Three Years | |||||||
Total Revenues, 3 Yr. CAGR % | - | 16.04 | 14.22 | 18.48 | 16.19 | ||
Gross Profit, 3 Yr. CAGR % | - | 17.92 | 13.31 | 17.11 | 17.32 | ||
EBITDA, 3 Yr. CAGR % | - | 29.59 | 6.77 | 14.19 | 14.51 | ||
EBITA, 3 Yr. CAGR % | - | 29.69 | 5.68 | 12.93 | 13.97 | ||
EBIT, 3 Yr. CAGR % | - | 29.26 | 2.6 | 10.6 | 9.52 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 33.51 | 7.44 | 14.52 | 11.36 | ||
Net Income, 3 Yr. CAGR % | - | 35.32 | 7.55 | 14.77 | 11.57 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 32.07 | 3.41 | 12.08 | 5.76 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | 35.32 | 7.55 | 14.71 | 11.11 | ||
Accounts Receivable, 3 Yr. CAGR % | - | 20.8 | 2.77 | 36.9 | 58.25 | ||
Inventory, 3 Yr. CAGR % | - | 28.95 | 18.56 | 9.49 | 5.95 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 12.49 | 17.4 | 16.37 | 10.38 | ||
Total Assets, 3 Yr. CAGR % | - | 30.54 | 24.18 | 23.36 | 44.78 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 15.37 | 18.05 | 17.93 | -18.77 | ||
Common Equity, 3 Yr. CAGR % | - | 29.67 | 28.73 | 25.63 | 32.54 | ||
Cash From Operations, 3 Yr. CAGR % | - | 15.28 | 19.14 | 23.7 | 37.93 | ||
Capital Expenditures, 3 Yr. CAGR % | - | 16.02 | 51.26 | 1.07 | -0.29 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | -1.84 | 27.84 | -22.41 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | -1.29 | 27.59 | -13.76 | ||
Compound Annual Growth Rate Over Five Years | |||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 15.72 | 15.76 | ||
Gross Profit, 5 Yr. CAGR % | - | - | - | 16.79 | 16.7 | ||
EBITDA, 5 Yr. CAGR % | - | - | - | 22.08 | 13.82 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 21.52 | 13.19 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 19.87 | 10.36 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 26.04 | 13.7 | ||
Net Income, 5 Yr. CAGR % | - | - | - | 27.02 | 14.08 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | 22.91 | 8.49 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | 26.99 | 13.8 | ||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 30.96 | 23.7 | ||
Inventory, 5 Yr. CAGR % | - | - | - | 13.6 | 18.42 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 13.33 | 11.5 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 23.81 | 40.48 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 22.58 | -7.86 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 27.1 | 32.68 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | 29.09 | 17.62 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | 1.16 | 15.11 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 0.33 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 6.06 |
- Stock Market
- Equities
- MANKIND Stock
- Financials Mankind Pharma Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















